Home › Funds › SNYDER CAPITAL MANAGEMENT L P › HALO

SNYDER CAPITAL MANAGEMENT L P position in HALO

HALOZYME THERAPEUTICS INC · Health Care

SNYDER CAPITAL MANAGEMENT L P reported holding 2,212,694 shares of HALO (HALOZYME THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$244.3M, representing 4.80% of its reported portfolio and ranking #3 among its reported holdings. SNYDER CAPITAL MANAGEMENT L P has disclosed HALO holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)2.21M sh
Reported value held$244.28M
Portfolio Weight4.80%
First reportedQ3 2023
Last changeReduce
Updated2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

How SNYDER CAPITAL MANAGEMENT L P's HALO position evolved

SNYDER CAPITAL MANAGEMENT L P first disclosed a stake in HALO in Q3 2023 at 4,324,232 shares (US$165.2M). The position peaked in Q3 2026 at 2,212,694 shares, worth US$244.3M. Across 13 filings, SNYDER CAPITAL MANAGEMENT L P increased the stake 4 time(s), trimmed it 8 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 2,212,694 shares valued at US$244.3M — a reduction of -183,407 shares quarter over quarter..

Quarter by quarter

QuarterSharesValueChange
Q3 2023 4.32M $165.19M New
Q4 2023 3.71M $142.95M Reduce
Q1 2024 4.12M $167.49M Add
Q2 2024 4.04M $211.53M Reduce
Q3 2024 4.06M $232.59M Add
Q4 2024 4.17M $199.29M Add
Q1 2025 3.67M $234.46M Reduce
Q2 2025 3.40M $176.75M Reduce
Q3 2025 2.73M $200.50M Reduce
Q4 2025 2.40M $161.47M Reduce
Q1 2026 2.32M $150.14M Reduce
Q2 2026 2.40M $187.54M Add
Q3 2026 2.21M $244.28M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About HALO and 13F data

HALO (HALOZYME THERAPEUTICS INC) is a Health Care company. 44 other funds we track also report a position in HALO — the largest reported positions include CONGRESS ASSET MANAGEMENT CO (US$251.9M), WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC (US$178.5M), FULLER & THALER ASSET MANAGEMENT, INC. (US$177.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding HALO

All HALO fund holders →

FAQ

How long has SNYDER CAPITAL MANAGEMENT L P held HALO?

SNYDER CAPITAL MANAGEMENT L P has disclosed HALO holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is SNYDER CAPITAL MANAGEMENT L P's current position in HALO?

As of Q3 2026, SNYDER CAPITAL MANAGEMENT L P holds 2.21M shares of HALO (HALOZYME THERAPEUTICS INC), valued at $244.28M, representing 4.80% of its reported portfolio and ranking #3.

Has SNYDER CAPITAL MANAGEMENT L P been buying or selling HALO?

In the latest 13F filing (Q3 2026), SNYDER CAPITAL MANAGEMENT L P reduced its position in HALO. The position peaked in Q3 2026 at 2.21M shares.

Which other funds hold HALO?

Other major institutional holders of HALO include CONGRESS ASSET MANAGEMENT CO, WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC, FULLER & THALER ASSET MANAGEMENT, INC., among 44 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.